A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-20 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
=== Gelatin === In 2021, Gelatin is a translucent, colorless, flavorless food ingredient, commonly derived from collagen taken from animal body parts. Gelita ranked second in the gelatin category of FoodTalks' Global Food Thickener Companies List.
=== Wound cleansing === Dirt or dust on the surface of the wound, bacteria, tissue that has died, and fluid from the wound may be cleaned. The evidence supporting the most effective technique is not clear and there is insufficient evidence to conclude whether cleaning wounds is beneficial for promoting healing or whether wound cleaning solutions (polyhexamethylene biguanide, aqueous hydrogen peroxide, etc.) are better than sterile water or saline solutions to help venous leg ulcers heal. It is uncertain whether the choice of cleaning solution or method of application makes any difference to venous leg ulcer healing.
In the industrialized world, the United States is the world's biggest consumer of prescription opioids, with Italy being one of the lowest, because of tighter regulations on prescribing narcotics for pain relief. Most opium imported into the United States is broken down into its alkaloid constituents, and whether legal or illegal, most current drug use occurs with processed derivatives such as heroin rather than with unrefined opium. Intravenous injection of opiates is most used: by comparison with injection, "dragon chasing" (heating of heroin on a piece of foil), and madak and "ack ack" (smoking of cigarettes containing tobacco mixed with heroin powder) are only 40 percent and 20 percent efficient, respectively. One study of British heroin addicts found a 12-fold excess mortality ratio (1.8 percent of the group dying per year). Most heroin deaths result not from overdose per se, but combination with other depressant drugs such as alcohol or benzodiazepines. The smoking of opium does not involve the burning of the material as might be imagined. Rather, the prepared opium is indirectly heated to temperatures at which the active alkaloids, chiefly morphine, are vaporized. In the past, smokers would use a specially designed opium pipe which had a removable knob-like pipe-bowl of fired earthenware attached by a metal fitting to a long, cylindrical stem.
=== Contraindications === A few contraindications should be taken into account for atomoxetine. The first one is hypersensitivity; patients known to be hypersensitive to atomoxetine or other constituents of the product should avoid using it. MAO inhibitors (MAOI) should also be taken into account for contraindications. Atomoxetine should not be taken within 2 weeks after discontinuing an MAOI or completely avoid taking MAOI. The same applies to treatment with an MAOI, that it should not be initiated within 2 weeks after discontinuing atomoxetine. Serious and sometimes fatal reactions may occur when atomoxetine and drugs that affect brain monoamine concentration are given concurrently or in close proximity. Examples of reactions are hyperthermia, inflexibility, myoclonus and altered mental states that include extreme agitation, possibly progressing to delirium and coma. Increased risk of mydriasis was associated with Strattera use in clinical trials. Therefore, the use of Strattera is not recommended in patients with narrow angle glaucoma. Patients with pheochromocytoma or a history of pheochromocytoma should not take Strattera because serious reactions (elevated blood pressure and tachyarrhythmia) have been reported in patients who received Strattera. Last but not least, patients with severe cardiac or vascular disorders should not be using Strattera. The only contraindication that is reported in the IMB Micromedex database is prior hypersensitivity to the active compound, reboxetine.
Sources: en.wikipedia.org
As a result, to be able to separate mixtures more efficiently, a subsequent LC analysis must employ very different separation selectivity relative to the first column. Another requirement to effectively use 2D liquid chromatography, according to Bushey and Jorgenson, is to employ highly orthogonal techniques which means that the two separation techniques must be as different as possible.
==== Buffer regions and midpoints ==== A titration curve for a diprotic acid contains two midpoints where pH=pKa. Since there are two different Ka values, the first midpoint occurs at pH=pKa1 and the second one occurs at pH=pKa2. Each segment of the curve that contains a midpoint at its center is called the buffer region. Because the buffer regions consist of the acid and its conjugate base, it can resist pH changes when base is added until the next equivalent points.
When IMS is used with mass spectrometry, ion mobility spectrometry-mass spectrometry offers many advantages, including better signal to noise, isomer separation, and charge state identification. IMS has commonly been attached to several mass spec analyzers, including quadropole, time-of-flight, and Fourier transform cyclotron resonance.
At the same time, the heart is stimulated via cholinergic parasympathetic nerves to beat more slowly (called bradycardia), ensuring that the inflow of blood into the arteries is reduced, thus adding to the reduction in pressure, and correcting the original error. Low pressure in the arteries, causes the opposite reflex of constriction of the arterioles, and a speeding up of the heart rate (called tachycardia). If the drop in blood pressure is very rapid or excessive, the medulla oblongata stimulates the adrenal medulla, via "preganglionic" sympathetic nerves, to secrete epinephrine (adrenaline) into the blood. This hormone enhances the tachycardia and causes severe vasoconstriction of the arterioles to all but the essential organs in the body (especially the heart, lungs, and brain). These reactions usually correct the low arterial blood pressure (hypotension) very effectively.
==== Australia ==== In July 2000, the first location in Australia opened in Sydney. After a massive downturn in 2008, the remaining Australian Starbucks stores were sold to the Withers family in 2014, with the company planning a more restrained expansion. As of November 2022, there are 59 Starbucks stores in Australia; 23 in New South Wales, 19 in Queensland and 18 in Victoria. These stores are spread out across Sydney, Melbourne, Brisbane, the Gold Coast, the Sunshine Coast and Ballarat. Before the mass-closure of 61 of their 85 stores in 2008, there were also stores in Adelaide, Canberra, Hobart and Wollongong. However, there are plans to open a restaurant in Toowoomba while the first store in Perth, Western Australia opened on October 23, 2024, with another 11 planned to open by the end of 2025.
Sources: en.wikipedia.org
Charles Frank Farthing CF (22 April 1953 – 6 April 2014) was a New Zealand doctor who specialised in the treatment of AIDS. He was the medical director of the AIDS Healthcare Foundation from 2001 to 2007. He later worked at Merck Sharp & Dohme as the director of medical affairs for infectious diseases in the Asia-Pacific.
=== In prokaryotes === Similar to eukaryotes, the production of rRNA is the rate-limiting step in the prokaryotic synthesis of a ribosome. In E. coli, it has been found that rRNA is transcribed from the two promoters P1 and P2 found within seven different rrn operons. The P1 promoter is specifically responsible for regulating rRNA synthesis during moderate to high bacterial growth rates. Because the transcriptional activity of this promoter is directly proportional to the growth rate, it is primarily responsible for rRNA regulation. An increased rRNA concentration serves as a negative feedback mechanism to ribosome synthesis. High NTP concentration has been found to be required for efficient transcription of the rrn P1 promoters. They are thought to form stabilizing complexes with RNA polymerase and the promoters. In bacteria specifically, this association of high NTP concentration with increased rRNA synthesis provides a molecular explanation as to why ribosomal and thus protein synthesis is dependent on growth-rate. A low growth-rate yields lower rRNA / ribosomal synthesis rates while a higher growth rate yields a higher rRNA / ribosomal synthesis rate. This allows a cell to save energy or increase its metabolic activity dependent on its needs and available resources. In prokaryotic cells, each rRNA gene or operon is transcribed into a single RNA precursor that includes 16S, 23S, 5S rRNA and tRNA sequences along with transcribed spacers. The RNA processing then begins before the transcription is complete.
Following the Viet Minh's defeats on the Hanoi perimeter, De Lattre decided to seize the city of Hòa Bình, 20 miles (32 km) west of the De Lattre Line, in an attempt to hinder the flow of supplies between Tonkin, which received direct Chinese support, and central and southern Vietnam. It also aimed to maintain the allegiance of the Muong troops. The city was captured by a parachute drop on November 14. The ensuing battle became increasingly costly to the French and after De Lattre fell ill from cancer and returned to Paris for treatment where he would die shortly thereafter in January 1952, his replacement as the overall commander of French forces in Indochina, General Raoul Salan, decided to pull back from the Hòa Bình salient. The French lost nearly 5,000 men and the Viet Minh "at least that number" according to historian Phillip P. Davidson, while Spencer C. Tucker claims 894 French killed and missing and 9,000 Viet Minh casualties. This campaign showed that the war was far from over. Throughout the war theater, the Việt Minh cut French supply lines and wore down the resolve of the French forces. There were continued raids, skirmishes and guerrilla attacks, but through most of the rest of the year each side withdrew to prepare for larger operations. In the Battle of Nà Sản, starting on October 2, French commanders began using "hedgehog" tactics, consisting in setting up well-defended outposts to get the Việt Minh out of the forests and force them to fight conventional battles instead of using guerrilla tactics.
=== Dynamics === Both experimental evidence and mathematical modeling indicate that p53 levels oscillate over time in response to cellular signals. These oscillations become more pronounced in the presence of DNA damage, such as double-stranded breaks or UV exposure. Modeling approaches also help illustrate how mutations in p53 isoforms affect oscillatory behavior, potentially informing tissue-specific therapeutic development.
== Differential diagnosis == The presentation of some cases is similar to that of Kearns–Sayre syndrome. Myoclonus epilepsy associated with ragged red fibers (MERRF) may be confused with MELAS as they both involve seizures, mental deterioration, and myopathy with ragged red fibers on biopsy. MERRF patients may also have hearing loss, visual disturbance secondary to optic atrophy, and short stature. The characteristic myoclonic seizure in MERRF may help to narrow diagnosis, but genetic testing should be considered to distinguish the two conditions. Leigh syndrome may also present with progressive neurological deterioration, seizures, and vomiting, mainly in young children.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.